[{"orgOrder":0,"company":"Totus Medicines","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ DCVC Bio","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ DCVC Bio"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ DCVC Bio","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ DCVC Bio"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"TOS-358","moa":"PI3K-alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Totus Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Totus Medicines","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Totus Medicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Totus Medicines \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Totus Medicines \/ Eli Lilly"}]

Find Clinical Drug Pipeline Developments & Deals by Totus Medicines

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Details : Under the terms of the agreement, Totus Medicines will use its proprietary OmniDEL platform to discover small molecule drug candidates against Lilly's undisclosed targets.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 16, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Eli Lilly

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Details : The net proceeds will be used for the advancement of company's pipeline of clinical candidates led by TOS-358, a covalent inhibitor of PI3Ka for the treatment of adults with select solid tumors.

                          Product Name : TOS-358

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 15, 2023

                          Lead Product(s) : TOS-358

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : DCVC Bio

                          Deal Size : $66.0 million

                          Deal Type : Series B Financing

                          blank

                          03

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Details : TOS-358 is the company's first-in-class covalent, highly specific, potent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations.

                          Product Name : TOS-358

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 13, 2023

                          Lead Product(s) : TOS-358

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Details : TOS-358, the first highly selective covalent molecule targeting PI3Kα, which is the most mutated oncogene in cancer, induces stasis and regression across PI3Kα mutant models.

                          Product Name : TOS-358

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 10, 2022

                          Lead Product(s) : TOS-358

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Details : TOS-358 is a highly selective covalent inhibitor of PI3Kα. TOS-358 demonstrates clear superiority compared to non-covalent molecules by achieving deep and durable inhibition of PI3K-AKT signaling.

                          Product Name : TOS-358

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 27, 2022

                          Lead Product(s) : TOS-358

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          RDD 2025
                          Not Confirmed
                          RDD 2025
                          Not Confirmed

                          Details : The Series A financing will be used to expand and scale Totus Medicines' proprietary drug discovery platform and advance the company's TOS-358 drug program targets the PI3K? mutation into the clinic.

                          Product Name : TOS-358

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 12, 2021

                          Lead Product(s) : TOS-358

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : DCVC Bio

                          Deal Size : $40.0 million

                          Deal Type : Series A Financing

                          blank